Stock Research for BPTH

BPTH

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BPTH Stock Chart & Research Data

The BPTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BPTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BPTH Due diligence Resources & Stock Charts

The BPTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BPTH Detailed Price Forecast - CNN Money CNN View BPTH Detailed Summary - Google Finance
Yahoo View BPTH Detailed Summary - Yahoo! Finance Zacks View BPTH Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BPTH Trends & Analysis - Trade-Ideas Barrons View BPTH Major Holders - Barrons
NASDAQ View BPTH Call Transcripts - NASDAQ Seeking View BPTH Breaking News & Analysis - Seeking Alpha
Spotlight View BPTH Annual Report - CompanySpotlight.com OTC Report View BPTH OTC Short Report - OTCShortReport.com
TradeKing View BPTH Fundamentals - TradeKing Charts View BPTH SEC Filings - Bar Chart
WSJ View Historical Prices for BPTH - The WSJ Morningstar View Performance/Total Return for BPTH - Morningstar
MarketWatch View the Analyst Estimates for BPTH - MarketWatch CNBC View the Earnings History for BPTH - CNBC
StockMarketWatch View the BPTH Earnings - StockMarketWatch MacroAxis View BPTH Buy or Sell Recommendations - MacroAxis
Bullish View the BPTH Bullish Patterns - American Bulls Short Pains View BPTH Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BPTH Stock Mentions - StockTwits PennyStocks View BPTH Stock Mentions - PennyStockTweets
Twitter View BPTH Stock Mentions - Twitter Invest Hub View BPTH Investment Forum News - Investor Hub
Yahoo View BPTH Stock Mentions - Yahoo! Message Board Seeking Alpha View BPTH Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BPTH - SECform4.com Insider Cow View Insider Transactions for BPTH - Insider Cow
CNBC View BPTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BPTH - OTC Markets
Yahoo View Insider Transactions for BPTH - Yahoo! Finance NASDAQ View Institutional Holdings for BPTH - NASDAQ


Stock Charts

FinViz View BPTH Stock Insight & Charts - FinViz.com StockCharts View BPTH Investment Charts - StockCharts.com
BarChart View BPTH Stock Overview & Charts - BarChart Trading View View BPTH User Generated Charts - Trading View




Latest Financial News for BPTH


Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering
Posted on Friday September 21, 2018

Bio-Path will issue to the investors warrants to purchase up to 2,261,538 shares of common stock, which represents 100% of the number of shares of common stock issued in the registered direct offering, with an exercise price $0.96 per share and exercise period commencing six (6) months following the issuance date and a term of five and one-half (5.5) years. Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes.


Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Posted on Wednesday August 29, 2018

HOUSTON, Aug. 29, 2018-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...


Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia
Posted on Monday August 27, 2018

Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it has commenced Stage 2 of the company’s Phase 2 trial of prexigebersen in acute myeloid leukemia. “We are delighted to announce the expansion of our ongoing Phase 2 clinical trial of prexigebersen for the treatment of acute myeloid leukemia using a dosing schedule that administers a greater amount of prexigebersen to the patient prior to commencing LDAC dosing than in the first part of the trial.


Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board
Posted on Thursday August 16, 2018

Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Jason B. Fleming, M.D., F.A.C.S., to its Scientific Advisory Board (SAB). “We are thrilled to welcome Dr. Fleming to our scientific advisory board. As a leader in the treatment of gastrointestinal cancers, Dr. Fleming will be able to offer substantial insight as we seek to advance our lead drug candidate prexigebersen and our third drug candidate, BP1003, towards the clinic for the treatment of pancreatic cancer,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.